This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cooper, M. L. Articles by Rayman, M. P. Search for Related Content PubMed PubMed Citation Articles by Cooper, M. L. Articles by Rayman, M. P.

Interaction between Single Nucleotide Polymorphisms in Selenoprotein P and Mitochondrial Superoxide Dismutase Determines Prostate Cancer Risk

¹ Faculty of Health and Medical Sciences, University of Surrey, Guildford, United Kingdom; ² Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; ³ Department of Epidemiology, Harvard School of Public Health, and ⁴ Dana-Farber/Harvard Cancer Center, Boston, Massachusetts

Requests for reprints: Margaret Rayman, Nutritional Sciences Division, Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7XH, United Kingdom. Phone: 44-1483-686447; Fax: 44-1483-686401; E-mail: m.rayman{at}surrey.ac.uk.

Key Words: mitochondrial superoxide dismutase • polymorphism • prostate cancer • selenium • selenoprotein P • SNPs

Selenium may affect prostate cancer risk via its plasma carrier selenoprotein P which shows dramatically reduced expression in prostate cancer tumors and cell lines. The selenoprotein P (SEPP1) Ala234 single nucleotide polymorphism (SNP) allele is associated with lower plasma selenoprotein P in men, reducing the concentration/activity of other antioxidant selenoproteins. Selenium status also modifies the effect of the mitochondrial superoxide dismutase (SOD2) SNP Ala16Val on prostate cancer risk. We investigated the relationship of these SNPs with prostate cancer risk. DNA from 2,975 cases and 1,896 age-matched controls from the population-based Prostate Cancer in Sweden study were genotyped using TaqMan assays. Cases were designated aggressive or nonaggressive prostate cancers at diagnosis by clinical criteria. Association with prostate cancer was investigated by logistic regression; gene-gene interaction using a general linear model. The mean plasma selenium concentration measured in 169 controls was relatively low (76.0 ± 17.2 µg/L). SNP genotype distributions were in Hardy-Weinberg equilibrium. SOD2-Ala16+ men were at a greater risk of prostate cancer [odds ratios (OR), 1.19; 95% confidence intervals (CI), 1.03–1.37] compared with SOD2-Val16 homozygotes. Men homozygous for SEPP1-Ala234 who were also SOD2-Ala16+ had a higher risk of prostate cancer (OR, 1.43; 95% CI, 1.17–1.76) and aggressive prostate cancer (OR, 1.60; 95% CI, 1.22–2.09) than those who were SOD2-Val16 homozygotes (interaction, prostate cancer P = 0.05; aggressive prostate cancer P = 0.01). This interaction was stronger in ever-smokers: SOD2-Ala16+ men homozygous for SEPP1-Ala234 had an almost doubled risk of prostate cancer (OR, 1.97; 95% CI, 1.33–2.91; interaction P = 0.001). In a low-selenium population, SOD2-Ala16+ men homozygous for SEPP1-Ala234 are at an increased risk of prostate cancer/aggressive prostate cancer especially if ever-smokers, because they are likely to produce more mitochondrial H₂O₂ that they cannot remove, thereby promoting prostate tumor cell proliferation and migration. [Cancer Res 2008;68(24):10171–7]

This article has been cited by other articles:

				E. A. Platz and S. M. Lippman Selenium, Genetic Variation, and Prostate Cancer Risk: Epidemiology Reflects Back on Selenium and Vitamin E Cancer Prevention Trial J. Clin. Oncol., August 1, 2009; 27(22): 3569 - 3572. [Full Text] [PDF]

				M. P. Rayman, G. F. Combs Jr, and D. J. Waters Selenium and Vitamin E Supplementation for Cancer Prevention JAMA, May 13, 2009; 301(18): 1876 - 1876. [Full Text] [PDF]

				B. Bekaert and M. P Rayman Plasma selenium concentration and prostate cancer risk Am. J. Clinical Nutrition, April 1, 2009; 89(4): 1276 - 1277. [Full Text] [PDF]

				D. L. Hatfield and V. N. Gladyshev The Outcome of Selenium and Vitamin E Cancer Prevention Trial (SELECT) Reveals the Need for Better Understanding of Selenium Biology Mol. Interv., February 1, 2009; 9(1): 18 - 21. [Abstract] [Full Text] [PDF]